Please try another search
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Alan Paul Chorlton | - | - | Member of Scientific Advisory Board |
Chris Frampton | - | - | Member of Scientific Advisory Board |
Julian C. Gilbert | 63 | 2020 | Senior Independent Non-Executive Chairman |
Andy Richards | - | 2017 | Chairman of Advisory Panel |
Derek Mann | - | 2018 | Member of Advisory Panel |
Madeleine Elizabeth Kennedy | 58 | 2020 | Independent Non-Executive Director |
Jeffery Lindeman | - | - | Member of Advisory Board |
Daniel John Gooding | 50 | 2017 | Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review